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Question 3
Answer: c. A recent systematic review and meta-analysis of data from published and unpublished randomised double-bind placebo-controlled trials of drug treatments in adults with neuropathic pain from a variety of causes estimated the number-needed-to-treat for capsaicin patches as 11 (compared with 6 for drugs such as duloxetine, 7 for gabapentin and 8 for pregabalin).
According to the National Institute for Health and Care Excellence (NICE), which one of the following is not a recommended first-line option for the treatment of painful diabetic peripheral neuropathy in a non-specialist setting? What role for capsaicin in diabetic peripheral neuropathy?
Answer: e. With the patch, more patients with peripheral diabetic neuropathy experienced treatment-emergent adverse effects associated with neurological function (11.8%) compared with the non-diabetic population (4.4%). The difference was mainly due to the difference in the reports of burning sensation (11.2% vs. 0.7%, respectively).
What proportion of patients with peripheral diabetic neuropathy who were treated with a capsaicin patch experienced treatment emergent adverse effects associated with neurological function? 
Question 4
Answer: a. In a double-blind trial, 369 patients were randomised to capsaicin patch (Qutenza) or a placebo patch. In the intentionto-treat population, the proportion of patients using the active patch that had at least a 30% reduction in pain was 40.9% (vs. 31.7% with placebo), but the significance of this difference was borderline (p=0.049).
